Momenta Loses in Appeals Court Over Watson’s Lovenox Copy
This article is for subscribers only.
Momenta Pharmaceuticals Inc. is unlikely to win its patent-infringement case over copies of the blood-thinner Lovenox, so Watson Pharmaceutics Inc. can sell its version until a trial is held, a U.S. appeals court ruled today.
The U.S. Court of Appeals for the Federal Circuit vacated an order that would have prevented Watson partner Amphastar Pharmaceuticals Inc. from selling the copy until an infringement trial can be held. The case was sent back to the lower court for further proceedings.